04:30 PM EDT, 06/11/2024 (MT Newswires) -- Innocan Pharma ( INNPF ) , on Tuesday said a preliminary safety evaluation of Innocan's single injection and sustained-release LPT-CBD conducted on minipigs showed the animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events.

Recognized by the FDA as an excellent model for toxicology, small breeds of miniature domestic pigs known as minipigs share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms.

In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month.

Encouragingly, the animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions.

"We are thrilled with these findings, which further underpin the safety profile of LPT-CBD following a single injection," said Dr. Eyal Kalo, the company's R&D Director, said in a statement. "With each new data point collected for LPT-CBD, we make significant strides in our quest to revolutionize patient care through sustained-release therapy. Our efforts to continuously gather data to fully characterize LPT-CBD are paramount in our journey towards its ultimate approval."